European Medicines Agency grants Priority Medicines (PRIME) designation to CTI-1601 for the treatment of Friedreich’s ataxia

CTI-1601 is a recombinant fusion protein intended to deliver human frataxin into the mitochondria of patients with Friedreich’s ataxia who are unable to produce enough of this essential protein. The designation was based on positive non-clinical and Phase I data.

Source:

Biospace Inc.